AstraZeneca Ends Manufacturing License at Indian Plant and Exits Site as Part of Global Strategy

AstraZeneca Pharma India Limited has surrendered its manufacturing license to the Drugs Controller and Licensing Authority, ending its direct manufacturing operations in India ahead of the license's December 2027 expiration12.

This move is part of a global strategic review, with AstraZeneca deciding to exit manufacturing at its only Indian site, located in Bangalore35.

The company will seek to position the Bangalore site for sale and is looking for a buyer who can potentially act as a contract manufacturing organization for products previously produced or packaged at the site, subject to statutory approval35.

AstraZeneca believes the exit will provide more value by transferring core manufacturing functions to a contract manufacturer, as the firm focuses on advancing innovation and research in India35.

The company reaffirmed its commitment to continuing its operations in India, focusing on research and development in Bangalore and expanding its IT and global capability center in Chennai5.

This decision follows a wider trend of multinational pharma companies restructuring their operations due to increasing competition from domestic Indian manufacturers and shifting business priorities35.

Sources:

1. https://scanx.trade/stock-market-news/corporate-actions/astrazeneca-pharma-india-exits-manufacturing-operations-surrenders-license/18360695

2. https://www.marketscreener.com/news/astrazeneca-pharma-india-surrenders-manufacturing-license-ce7c50d3de8df424

3. https://timesofindia.indiatimes.com/city/delhi/astrazeneca-exit-manufacturing-india-global-review/articleshow/105275280.cms

5. https://timesofindia.indiatimes.com/business/india-business/astrazeneca-to-exit-india-manufacturing-as-part-of-global-review/articleshow/105272113.cms